Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially

Franco Pissani, Delphine Malherbe, Harlan Robins, Victor De Filippis, Byung Park, George Sellhorn, Leonidas Stamatatos, Julie Overbaugh, Nancy Haigwood

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

HIV-1 infection results in the development of a diverging quasispecies unique to each infected individual. Envelope (Env)-specific neutralizing antibodies (NAbs) typically develop over months to years after infection and initially are limited to the infecting virus. In some subjects, antibody responses develop that neutralize heterologous isolates (HNAbs), a phenomenon termed broadening of the NAb response. Studies of co-crystalized antibodies and proteins have facilitated the identification of some targets of broadly neutralizing monoclonal antibodies (NmAbs) capable of neutralizing many or most heterologous viruses; however, the ontogeny of these antibodies in vivo remains elusive. We hypothesize that Env protein escape variants stimulate broad NAb development in vivo and could generate such NAbs when used as immunogens. Here we test this hypothesis in rabbits using HIV Env vaccines featuring: (1) use of individual quasispecies env variants derived from an HIV-1 subtype A-infected subject exhibiting high levels of NAbs within the first year of infection that increased and broadened with time; (2) motif optimization of envs to enhance in vivo expression of DNA formulated as vaccines; and (3) a combined DNA plus protein boosting regimen. Vaccines consisted of multiple env variants delivered sequentially and a simpler regimen that utilized only the least and most divergent clones. The simpler regimen was as effective as the more complex approach in generating modest HNAbs and was more efficient when modified, motif-optimized DNA was used in combination with trimeric gp140 protein. This is a rationally designed strategy that facilitates future vaccine design by addressing the difficult problem of generating HNAbs to HIV by empirically testing the immunogenicity of naturally occurring quasispecies env variants.

Original languageEnglish (US)
Pages (from-to)5519-5526
Number of pages8
JournalVaccine
Volume30
Issue number37
DOIs
StatePublished - Aug 10 2012

Fingerprint

DNA Vaccines
recombinant vaccines
Neutralizing Antibodies
neutralizing antibodies
HIV
vaccines
Vaccines
Human immunodeficiency virus 1
antibodies
HIV-1
Proteins
DNA
proteins
infection
Viruses
AIDS Vaccines
viruses
Nucleotide Motifs
Antibodies
Infection

Keywords

  • DNA
  • Envelope
  • HIV
  • Neutralizing antibodies
  • Prime-boost

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially. / Pissani, Franco; Malherbe, Delphine; Robins, Harlan; De Filippis, Victor; Park, Byung; Sellhorn, George; Stamatatos, Leonidas; Overbaugh, Julie; Haigwood, Nancy.

In: Vaccine, Vol. 30, No. 37, 10.08.2012, p. 5519-5526.

Research output: Contribution to journalArticle

Pissani, F, Malherbe, D, Robins, H, De Filippis, V, Park, B, Sellhorn, G, Stamatatos, L, Overbaugh, J & Haigwood, N 2012, 'Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially', Vaccine, vol. 30, no. 37, pp. 5519-5526. https://doi.org/10.1016/j.vaccine.2012.06.042
Pissani, Franco ; Malherbe, Delphine ; Robins, Harlan ; De Filippis, Victor ; Park, Byung ; Sellhorn, George ; Stamatatos, Leonidas ; Overbaugh, Julie ; Haigwood, Nancy. / Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially. In: Vaccine. 2012 ; Vol. 30, No. 37. pp. 5519-5526.
@article{4ce5c49feeaf4d3cad1c7c935acb45f7,
title = "Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially",
abstract = "HIV-1 infection results in the development of a diverging quasispecies unique to each infected individual. Envelope (Env)-specific neutralizing antibodies (NAbs) typically develop over months to years after infection and initially are limited to the infecting virus. In some subjects, antibody responses develop that neutralize heterologous isolates (HNAbs), a phenomenon termed broadening of the NAb response. Studies of co-crystalized antibodies and proteins have facilitated the identification of some targets of broadly neutralizing monoclonal antibodies (NmAbs) capable of neutralizing many or most heterologous viruses; however, the ontogeny of these antibodies in vivo remains elusive. We hypothesize that Env protein escape variants stimulate broad NAb development in vivo and could generate such NAbs when used as immunogens. Here we test this hypothesis in rabbits using HIV Env vaccines featuring: (1) use of individual quasispecies env variants derived from an HIV-1 subtype A-infected subject exhibiting high levels of NAbs within the first year of infection that increased and broadened with time; (2) motif optimization of envs to enhance in vivo expression of DNA formulated as vaccines; and (3) a combined DNA plus protein boosting regimen. Vaccines consisted of multiple env variants delivered sequentially and a simpler regimen that utilized only the least and most divergent clones. The simpler regimen was as effective as the more complex approach in generating modest HNAbs and was more efficient when modified, motif-optimized DNA was used in combination with trimeric gp140 protein. This is a rationally designed strategy that facilitates future vaccine design by addressing the difficult problem of generating HNAbs to HIV by empirically testing the immunogenicity of naturally occurring quasispecies env variants.",
keywords = "DNA, Envelope, HIV, Neutralizing antibodies, Prime-boost",
author = "Franco Pissani and Delphine Malherbe and Harlan Robins and {De Filippis}, Victor and Byung Park and George Sellhorn and Leonidas Stamatatos and Julie Overbaugh and Nancy Haigwood",
year = "2012",
month = "8",
day = "10",
doi = "10.1016/j.vaccine.2012.06.042",
language = "English (US)",
volume = "30",
pages = "5519--5526",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "37",

}

TY - JOUR

T1 - Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially

AU - Pissani, Franco

AU - Malherbe, Delphine

AU - Robins, Harlan

AU - De Filippis, Victor

AU - Park, Byung

AU - Sellhorn, George

AU - Stamatatos, Leonidas

AU - Overbaugh, Julie

AU - Haigwood, Nancy

PY - 2012/8/10

Y1 - 2012/8/10

N2 - HIV-1 infection results in the development of a diverging quasispecies unique to each infected individual. Envelope (Env)-specific neutralizing antibodies (NAbs) typically develop over months to years after infection and initially are limited to the infecting virus. In some subjects, antibody responses develop that neutralize heterologous isolates (HNAbs), a phenomenon termed broadening of the NAb response. Studies of co-crystalized antibodies and proteins have facilitated the identification of some targets of broadly neutralizing monoclonal antibodies (NmAbs) capable of neutralizing many or most heterologous viruses; however, the ontogeny of these antibodies in vivo remains elusive. We hypothesize that Env protein escape variants stimulate broad NAb development in vivo and could generate such NAbs when used as immunogens. Here we test this hypothesis in rabbits using HIV Env vaccines featuring: (1) use of individual quasispecies env variants derived from an HIV-1 subtype A-infected subject exhibiting high levels of NAbs within the first year of infection that increased and broadened with time; (2) motif optimization of envs to enhance in vivo expression of DNA formulated as vaccines; and (3) a combined DNA plus protein boosting regimen. Vaccines consisted of multiple env variants delivered sequentially and a simpler regimen that utilized only the least and most divergent clones. The simpler regimen was as effective as the more complex approach in generating modest HNAbs and was more efficient when modified, motif-optimized DNA was used in combination with trimeric gp140 protein. This is a rationally designed strategy that facilitates future vaccine design by addressing the difficult problem of generating HNAbs to HIV by empirically testing the immunogenicity of naturally occurring quasispecies env variants.

AB - HIV-1 infection results in the development of a diverging quasispecies unique to each infected individual. Envelope (Env)-specific neutralizing antibodies (NAbs) typically develop over months to years after infection and initially are limited to the infecting virus. In some subjects, antibody responses develop that neutralize heterologous isolates (HNAbs), a phenomenon termed broadening of the NAb response. Studies of co-crystalized antibodies and proteins have facilitated the identification of some targets of broadly neutralizing monoclonal antibodies (NmAbs) capable of neutralizing many or most heterologous viruses; however, the ontogeny of these antibodies in vivo remains elusive. We hypothesize that Env protein escape variants stimulate broad NAb development in vivo and could generate such NAbs when used as immunogens. Here we test this hypothesis in rabbits using HIV Env vaccines featuring: (1) use of individual quasispecies env variants derived from an HIV-1 subtype A-infected subject exhibiting high levels of NAbs within the first year of infection that increased and broadened with time; (2) motif optimization of envs to enhance in vivo expression of DNA formulated as vaccines; and (3) a combined DNA plus protein boosting regimen. Vaccines consisted of multiple env variants delivered sequentially and a simpler regimen that utilized only the least and most divergent clones. The simpler regimen was as effective as the more complex approach in generating modest HNAbs and was more efficient when modified, motif-optimized DNA was used in combination with trimeric gp140 protein. This is a rationally designed strategy that facilitates future vaccine design by addressing the difficult problem of generating HNAbs to HIV by empirically testing the immunogenicity of naturally occurring quasispecies env variants.

KW - DNA

KW - Envelope

KW - HIV

KW - Neutralizing antibodies

KW - Prime-boost

UR - http://www.scopus.com/inward/record.url?scp=84864319075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864319075&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.06.042

DO - 10.1016/j.vaccine.2012.06.042

M3 - Article

VL - 30

SP - 5519

EP - 5526

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 37

ER -